NAAG Submits Comment Letter on Beneficial Ownership Regulations

Our comments are consistent with the sense of Congress, which requires that regulations “to the greatest extent practicable… collect information in a form and manner that is reasonably designed to generate a database that is highly useful to… law enforcement agencies…” NDAA § 6402(8)(C).

Read More →

In re: Franchise No Poaching Provisions, King Cty. Super Ct., Wash. 2019

The Attorney General of Washington has entered into a series of agreements with 75 national chains who included so-called “no-poach” provisions in their franchise agreements. No-poach clauses appear in franchise agreements between owners of franchises and corporate headquarters. The clauses prohibit employees from moving among stores in the same corporate chain, a practice that economists…

Read More →

Alabama et al. v. Endo International, No. 3:19-cv-04157 (N.D. Cal. July 19, 2019)

Eighteen states reached a settlement with Endo Pharmaceuticals Inc. under which Endo paid $2.3 million to settle allegations it entered into a reverse-payment agreement to obstruct generic competition to Lidoderm, a pain relief patch frequently used to treat shingles. According to the complaint, Endo had an agreement with Watson Laboratories Inc. ensuring Endo would not face…

Read More →

Washington v. Starkist Company, No. 20-2-09491-9 (Wash. Super. Ct. King Cty. June 2, 2020)

Plaintiff state filed a civil lawsuit against Starkist, one of the world’s largest canned tuna manufacturers and the former CEO of Bumble Bee Foods, another large tuna manufacturer, over a price-fixing conspiracy that drove up the cost of packaged tuna for more than a decade. The suit alleged that StarKist Co., its parent company Dongwon,…

Read More →

Settlement Agreement Between Plaintiff States and UBS (Dec. 21, 2018)

Forty plaintiff states reached a $68 million settlement with UBS for fraudulent conduct involving interest rate manipulation that had a significant impact on consumers and financial markets around the world. UBS’ fraudulent conduct involved the manipulation of LIBOR (the London Interbank Offered Rate). LIBOR is a benchmark interest rate that affects financial instruments worth trillions…

Read More →

Attorneys General Urge Senate to Pass Law to Fight Shell Companies

As our States’ chief legal officers, we are concerned about the use of American financial institutions for money laundering by terrorist groups and other criminal enterprises.

Read More →

NAAG Endorses Stopping Overdoses of Fentanyl Analogues (SOFA) Act

States and localities are on the front line of this crisis and are a large part of winning the battle from both a law enforcement and public health perspective.

Read More →

Washington v. LG Electronics (Philips settlement), No. 12-2-15842 (King Cty Super. Ct., Wash. June 14, 2018

The state alleged that Philips participated in an unlawful conspiracy with other CRT manufacturers(including LG< Panasonic, Hitachi, Chungwha, Toshiba and Samsung, to raise, fix, maintain, or stabilize the price of Cathode Ray Tubes at artificially high levels and to maintain the quantities of CRTs at artificially low levels, in violation of Washington's consumer protection and antitrust statutes. The state alleged this conspiracy continued from 1995 to 2007.The lawsuit alleges Philips representatives attended secret meetings with other companies, known internally as "glass meetings,†in which they agreed to fix prices of CRTs. For example, the companies agreed to artificially restrict supply to keep prices high and share information with competitors regarding capacity, production, prices and customer demands for CRTs.According to the lawsuit, conspirators split the glass meetings into three tiers: "top meetings†for high-level company executives, "management meetings†for mid-level managers, and "working-level meetings†for lower-level sales and marketing employees. Philips attended meetings at all three levels. The lawsuit alleges the companies' scheme allowed them to keep CRT prices high, even as liquid crystal display, or LCD, screens were introduced to the market. Philips no longer produces CRTs. Philips agreed to pay $7 million to recompense Washington consumers.

Read More →

Washington v. LG Electronics (Samsung settlement), No. 12-2-15842 (King Cty Super. Ct., Wash. June 14, 2018

The state alleged that Samsung participated in an unlawful conspiracy with other CRT manufacturers(including LG, Panasonic, Hitachi, Chungwha, Toshiba and Philips, to raise, fix, maintain, or stabilize the price of Cathode Ray Tubes at artificially high levels and to maintain the quantities of CRTs at artificially low levels, in violation of Washington’s consumer protection and antitrust statutes. The state alleged this conspiracy continued from 1995 to 2007.The lawsuit alleges Samsung representatives attended secret meetings with other companies, known internally as “glass meetings,†in which they agreed to fix prices of CRTs. For example, the companies agreed to artificially restrict supply to keep prices high and share information with competitors regarding capacity, production, prices and customer demands for CRTs.According to the lawsuit, conspirators split the glass meetings into three tiers: “top meetings†for high-level company executives, “management meetings†for mid-level managers, and “working-level meetings†for lower-level sales and marketing employees. Samsung attended meetings at all three levels. The lawsuit alleges the companies’ scheme allowed them to keep CRT prices high, even as liquid crystal display, or LCD, screens were introduced to the market. Samsung no longer produces CRTs. Philips agreed to pay $7 million to recompense Washington consumers.

Read More →

California et al. v. Teikoku Seikayu Co.(Lidoderm), No. 3:18-cv-00675 (N.D. Cal. 01/31/18)

Plaintiff states alleged that defendant, the producer of Lidoderm (pain medication), paid or incentivized generic drug makers to delay entry into market to protect its monopoly on Lidoderm. (“pay for delay”) The settlement agreement, which expires in twenty years, prohibits Teikoku from entering into agreements that restrict generic drug manufacturers from researching, manufacturing, marketing, or selling products for a period of time and requires Teikoku to cooperate in an ongoing investigation into similarly anticompetitive conduct by other drug manufacturers, among other things.

Read More →